A Pilot Study to Determine the Safety and Efficacy of Monochromatic Excimer Light in the Treatmentof Vitiligo
March 2008 | Volume 7 | Issue 3 | Original Article | 258 | Copyright © March 2008
Stacy M. Chimento BA, Meggan Newland MD, Carlos Ricotti MD, Steven Nistico MD, Paolo Romanelli MD
Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood’s light examination was not documented.
Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period.
Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.